AVALO THERAPEUTICS INC
AVTX · NASDAQ
Updated at 2026-10-14 08:52:42
- Today's High
- $13.23
- Today’s Low
- $11.99
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $13.56
- Previous Close
- $13.24
- Volume
- 502.77K
- Market Cap
- $710.06M
- P/E Ratio
- --
- EPS
- $-4.75
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 1500 LIBERTY RIDGE DRIVE, WAYNE, PA, UNITED STATES, 19087
- Country
- US
- Listing Date
- 2015-11-13
- Fiscal Year End
- December
- Shares Outstanding
- 52.9M
- CIK
- 0001534120
- Website
- www.avalotx.com
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly those related to immunological regulation. With a robust pipeline of proprietary drug candidates, Avalo is dedicated to addressing critical unmet medical needs in areas where effective treatments remain scarce. Leveraging in-depth insights into disease mechanisms alongside a rigorous clinical trial methodology, the company is well-positioned to achieve significant advancements in patient care. Through its patient-centric approach, Avalo not only seeks to improve therapeutic outcomes but also aims to make a substantial impact on the lives of those it serves, establishing itself as a noteworthy player in the biopharmaceutical landscape.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$59K
2025-09-30
$0
Operating Expenses
2026-06-30
$31.51M
2026-03-31
$20.88M
2025-12-31
$19.8M
2025-09-30
$9.2M
Net Income
2026-06-30
-$36.35M
2026-03-31
-$19.63M
2025-12-31
-$13.72M
2025-09-30
-$30.62M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
-23.25K%
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.83
2026-03-31
$-0.98
2025-12-31
$-0.37
2025-09-30
$-2.19
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$36.32M
2026-03-31
-$19.6M
2025-12-31
-$13.57M
2025-09-30
-$30.55M
Effective Tax Rate
2026-06-30
-0.04%
2026-03-31
-0.06%
2025-12-31
-0.95%
2025-09-30
-0.03%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $59K | $0 |
| Operating Expenses | $31.51M | $20.88M | $19.8M | $9.2M |
| Net Income | -$36.35M | -$19.63M | -$13.72M | -$30.62M |
| Net Profit Margin | -- | -- | -23.25K% | -- |
| Earnings Per Share | $-0.83 | $-0.98 | $-0.37 | $-2.19 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$36.32M | -$19.6M | -$13.57M | -$30.55M |
| Effective Tax Rate | -0.04% | -0.06% | -0.95% | -0.03% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.